Effectiveness of Betaserc® (Betahistine Dihydrochloride) in Patients With Vestibular Vertigo in Routine Practice (VIRTUOSO)

• Scale for Vestibular Vertigo Severity Level and Clinical Response Evaluation (SVVSLCRE) [ Time Frame: Up to 2 months ] [ Designated as safety issue: No ]
  Number and proportion of patients with clinical response on treatment determined with SVVSLCRE
  
  

• Change of the patient's clinical conditions of vestibular vertigo from baseline to the end of observational treatment period [ Time Frame: From Day 0 to 2 months ] [ Designated as safety issue: No ]
  determined with the Scale for Vestibular Vertigo Severity Level and Clinical Response Evaluation (SVVSLCRE)
  
  
• Change of vestibular vertigo attacks frequency from baseline to the end of observational treatment period [ Time Frame: From Day 0 to 2 months ] [ Designated as safety issue: No ]
  
• Change of vestibular vertigo attacks frequency from the end of observational treatment period to the end of follow-up period [ Time Frame: From 2 months to 4 months ] [ Designated as safety issue: No ]
  
• Overall clinical response assessed by physician [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  determined with a four-point-scale, where 4 = excellent, 3 = good, 2 = fair, and 1 = poor.
  
  
• Overall clinical response assessed by patient [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  determined with a four-point-scale, where 4 = excellent, 3 = good, 2 = fair, and 1 = poor.
  
  
• Clinical response as improvement of vertigo associated symptoms evaluated by physician [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  vertigo associated symptoms: tinnitus, hearing loss, nausea, vomiting, faintness and headache; determined with a four-point-scale, where 4 = excellent, 3 = good, 2 = fair, and 1 = poor.
  
  
• Clinical response as improvement of vertigo associated symptoms evaluated by patient [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  vertigo associated symptoms: tinnitus, hearing loss, nausea, vomiting, faintness and headache; determined with a four-point-scale, where 4 = excellent, 3 = good, 2 = fair, and 1 = poor.
  
  

A prospective, multicentre, non-interventional, non-randomized, non-controlled, single arm, post-marketing observational program in patients whom betahistine dihydrochloride (Betaserc®) tablets were prescribed in the usual manner at the maximal recommended daily dose of 48 mg in accordance with the locally approved label. Over a program period physician is free to adjust betahistine dihydrochloride dose according to country approved label. Adult outpatients with vestibular vertigo who can be treated with betahistine dihydrochloride as per the locally approved label will be enrolled in the program. The program consists of an observational treatment period (up to 2 months) and a follow-up period (up to 2 months, for evaluation of the course of vestibular vertigo after treatment completion).